CD33 and leukemia: Monitoring CD33 + or CD45 + cells from the bone marrow, ME2 silencing in both shME2-THP-1 (Fig. 3F and G) and shME2-MV4-11 (Fig. 3H and I, respectively) mice resulted in a significant decrease of AML cells, which may be attributed to the impairment of ME2-associated energy metabolism and redox balance, suggesting a positive role for ME2 in the development of leukemia.